BC Week In Review | Apr 20, 2015
Company News

Can-Fite, Cipher deal

Can-Fite granted Cipher rights to commercialize Can-Fite’s CF101 in Canada to treat moderate to severe psoriasis and rheumatoid arthritis. The adenosine A3 receptor (ADORA3) agonist has completed a Phase II/III trial to treat psoriasis and...
BC Week In Review | Mar 16, 2015
Clinical News

Beteflam Patch regulatory update

Health Canada accepted for review an NDS for Beteflam Patch from Cipher Pharmaceuticals Inc. (TSX:CPH; NASDAQ:CPHR, Mississauga, Ontario) to treat inflammatory skin conditions, including chronic plaque psoriasis. The company said it expects a decision at...
BioCentury | Oct 1, 2012
Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
BC Week In Review | Aug 13, 2012
Company News

Cipher, Institut Biochimique sales and marketing update

Cipher received exclusive Canadian rights to market Institut's Betesil Patch to treat inflammatory skin conditions, including plaque psoriasis. The self-adhesive medicated plaster containing 0.1% betamethasone valerate is already marketed in the U.K., France, Greece, Hungary...
Items per page:
1 - 4 of 4